[Eight-year study on the treatment with intravenous midazolam for status epilepticus and clusters of seizures in children]

No To Hattatsu. 2003 Nov;35(6):484-90.
[Article in Japanese]

Abstract

Eighty-two episodes of status epilepticus or clusters of seizures in 45 children were treated with intravenous midazolam. Twenty-two children had epilepsy and 23 had acute symptomatic seizures. Midazolam was administered as an intravenous bolus dose at 0.06-0.4 mg/kg (mean 0.173 mg/kg), followed by continuous intravenous infusion at 0.05-0.4 mg/kg/hr (mean 0.191 mg/kg/hr). The mean duration of the treatment was 132.7 hours. Complete arrest of seizures was achieved in 62 episodes, and decrease by more than 50% in seizure frequency in 8 clusters of seizures. In these 70 successfully treated cases (85.4%), the effect appeared within 45 minutes after the initiation of therapy. No severe adverse effects were noted except stridor and mild respiratory suppression in 2 cases. Midazolam is an effective and safe drug to be used in a first-line or second-line therapy for status epilepticus and clusters of seizures in children.

Publication types

  • Clinical Trial
  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Humans
  • Infant
  • Infusions, Intravenous
  • Injections, Intravenous
  • Midazolam / administration & dosage*
  • Seizures / drug therapy*
  • Status Epilepticus / drug therapy*
  • Time Factors
  • Treatment Outcome

Substances

  • Midazolam